Targeting Tumor-Associated Macrophages with PI3Kγ Inhibitor-loaded Nanocarriers for Cancer Therapy
2020-12
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Targeting Tumor-Associated Macrophages with PI3Kγ Inhibitor-loaded Nanocarriers for Cancer Therapy
Authors
Published Date
2020-12
Publisher
Type
Thesis or Dissertation
Abstract
AbstractMacrophages exist in virtually all organs and are central players in normal immune functions. They are also key regulators in the pathogenesis of various human diseases, including cancer. Once in tumors, these cells can adopt a tumor-promoting phenotype named tumor-associated macrophages (TAMs). TAMs contribute to tumor growth in many ways, such as immunosuppression, angiogenesis, and metastasis. [1]
PI3Kγ is a signal-transducing enzyme that mediates the key cellular functions in cancer and immunity. It is highly expressed in TAMs and plays an important role in the pro-tumor function of these cells. Inhibit its activity can lead to the expression of pro-inflammatory factors, then stimulate cytotoxic T cell activation, anti-tumor immunity, and promote tumor regression.[2] IPI549 is a potent and highly selective inhibitor of PI3kγ. It can repolarize TAMs toward a pro-inflammatory phenotype, which suppresses tumor growth. It also demonstrates robust inhibition of PI3K-γ mediated neutrophil migration in-vivo. [3]
CRV is a macrophage-targeting peptide. It can specifically bind to the RXRB receptor, which expresses in TAMs. After systemic administration, rapid and efficient homing of CRV to the TAMs can be observed. [4] Since the PI3kγ expressed in both tumor and healthy tissues, CRV could be utilized as the ligand, which specifically targeting to TAMs and concentrates the IPI549 at TAMs.
Due to the low solubility and potential side effects of IPI549, nanocarriers (liposomes and exosomes) which are decorated with CRV peptide, are utilized to load IPI549. It was expected to enhance the specific uptake of the compound by TAMs in-vivo.
Methods and Results
Two strategies were used to enhance the loading efficiency. First, 1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol) (DSPE-PEG2000) and Egg phosphatidylcholine (EPC) were used to build the phospholipid bilayer. The unsaturated and saturated phosphatidylcholines, with a significant difference in phase transition temperature and chain stiffness, created bilayer "pockets" in which the bulky IPI549 is embedded. Meanwhile, DSPE-PEG2000 micelles encapsulate IPI549 in a hydrophobic cavity, then fusion with the phospholipid bilayer of liposomes further increases the drug loading. Exosomes secreted by RAW cells were isolated and collected by ultra-centrifuging. CRV was decorated on the surface of nanocarriers (exosomes and liposomes) through incubation methods.
Conclusion
25% IPI549 to phospholipid molar ratio, a relatively high drug loading compared to other insoluble drugs, was attained during liposome preparation. After systemic administration, rapid and efficient homing of CRV-IPI549 liposomes to the tumors could be observed. The decorated ligands（TAT and RPAR）of the exosomes still keep the combination activity with their receptors (heparin and neuropilin 1 receptor b1b2 domain protein). The decorated ligands do not inhibit the uptake of exosomes by macrophages.
Keywords: TAM; PI3Kγ inhibitor; CRV peptide; liposomes; exosomes.
Description
University of Minnesota M.S. thesis. 2020. Major: Pharmaceutics. Advisor: Hongbo Pang. 1 computer file (PDF); 56 pages.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Wang, Yihan. (2020). Targeting Tumor-Associated Macrophages with PI3Kγ Inhibitor-loaded Nanocarriers for Cancer Therapy. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/219271.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.